- Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever Barron’s
- Cytokinetics Skyrockets On ‘Provocative’ Results In Heart Disease Investor’s Business Daily
- Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows statnews.com
- Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) Seeking Alpha
- Promising Phase 3 Trial Results Bolster Buy Rating for Cytokinetics’ Aficamten TipRanks
Source link
